Defects in apoptosis that evolve during the course of cancer progression not only provide cancer cells with intrinsic survival advantage, but also provide inherent resistance to chemotherapeutic agents. Thus, modulation of apoptosis by targeting components of the apoptotic machinery and its regulators to restore apoptotic function is a rational approach for treating cancer. With our increasing knowledge of the mechanisms of apoptosis regulation and of how apoptosis is disabled in cancer cells, numerous novel approaches targeting apoptotic pathways can now be exploited for cancer therapy. While most of these therapies are still in preclinical development, some have shown considerable promise and progressed into the clinic. This chapter summarizes the current knowledge of the apoptotic pathways and provides a selective review on the development of drugs that target the apoptotic machinery.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams, J. M. (2003). Ways of dying: multiple pathways to apoptosis. Genes Dev 17 2481–2495.
Altieri, D. C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581–8589.
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155–162.
Balint, E. E. and Vousden, K. H. (2001). Activation and activities of the p53 tumour suppressor protein. Br J Cancer 85, 1813–1823.
Balkwill, F., Charles, K. A., and Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211–217.
Brummelkamp, T. R., Nijman, S. M. B., Dirac, A. M. G., and Bernards, R. (2003). Loss of the cylindromatosis tumor suppressor inhibits apoptosis by activating NF-BB. Nature 424, 797–801.
Bykov, V. J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., and Selivanova, G. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8, 282–288.
Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R., and Kroemer, G. (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825–2837.
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., Ovaa, H., Berkers, C., Nicholson, B., Chao, T. H., Neuteboom, S. T. C., Richardson, P., Palladino, M. A., and Anderson, K. C. (2005). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407–354.
Chan, S. L., Lee, M. C., Tan, K. O., Yang, L. K., Lee, A. S., Flotow, H., Fu, N. Y., Butler, M. S., Soejarto, D. D., Buss, A. D., and Yu, V. C. (2003). Identification of chelerythrine as an inhibitor of Bcl-XL function. J Biol Chem 278, 20453–20456.
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., and Huang, D. C. S. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17, 393–403.
Cheng, E., Wei, M., Weiler, S., Flavell, R., Mak, T., Lindsten, T., and Korsmeyer, S. (2001). BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8, 705–711.
Comis, R. L. (2005). The current situation: Erlotinib (Tarceva) and Gefitinib (Iressa) in non-small cell lung cancer. Oncologist 10, 467–470.
Cory, S. and Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, 647–656.
Cory, S. and Adams, J. M. (2005). Killing cancer cells by flipping the BCL-2/BAX switch. Cancer Cell 7, 5–6.
Cuconati, A., Mukherjee, C., Perez, D., and White, E. (2003). DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev, 2922–2932.
Cuconati, A. and White, E. (2002). Viral homologues of Bcl-2: role of apoptosis in the regulation of virus infection. Genes Dev 16, 2465–2478.
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000). Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18, 1185–1190.
Danial, N. N. and Korsmeyer, S. J. (2004). Cell death: critical control points. Cell 116, 205–219.
Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., Scurr, M., Hagemeijer, A., van Oosterom, A. T., and Group (2004). Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40, 689–695.
Del Bufalo, D., Trisciuoglio, D., Scarsella, M., Zangemeister-Wittke, U., and Zupi, G. (2003). Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22, 8441–8447.
Dimmeler, S., Breitschopf, K., Haendeler, J., and Zeiher, A. M. (1999). Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 189, 1815–1822.
Downward, J. (2004). PI3-kinase, Akt and cell survival. Semin Cell Dev Biol 15, 177–182.
Druker, B. J. (2004). Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91, 1–30.
Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999). Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68, 383–424.
Eggermont, A. M. and ten Hagen, T. L. (2001). Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits and future perspectives. Curr Oncol Rep 3, 359–367.
Emens, L. A. (2005). Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 12, 243–253.
Essafi, A., Fernandez de Mattos, S., and Hassen, Y. A. M. (2005). Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24, 2317–2329.
Faderl, S., Talaz, M., Estrov, Z., O’Brien, S., Kurzrock, R., and Kantarjian, H. M. (1999). The biology of chronic myeloid leukemia. N Engl J Med 341, 164–172.
Fennell, D. A., Corbo, M. V., Dean, N. M., Monia, B. P., and Cotter, F. E. (2001). In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukemia cell death in a SCID/NOD Hu model. Br J Haematol 112, 706–713.
Fesik, S. W. (2000). Insights into programmed cell death through structural biology. Cell 103, 273–282.
Fesik, S. W. and Shi, Y. (2001). Controlling the caspases. Science 294, 1477–1478.
Fischer, U. and Schulze-Osthoff, K. (2005). New approaches and therapeutics targeting apoptosis in disease. Pharmacological reviews 57, 187–215.
Fischer, U., Janicke, R. U., and Schulze-Osthoff, K. (2003). Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10, 76–100.
Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510.
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rudiger, S., and Fersht, A. R. (2002). A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99, 937–942.
Fuentes-Prior, P. and Salvesen, G. S. (2004). The protein structures that shape caspase activity, specificity, activation and inhibition. Biochemical J 384, 201–232.
Fulda, S., Wick, W., Weller, M., and Debatin, K. M. (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8, 808–815.
Garkavtsev, I. (2004). The candidate tumor suppressor protein ING4 regulates brain tumor growth and angiogenesis. Nature 428, 328–332.
Gelinas, C. and White, E. (2005). BH3-only proteins in control: Specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 19, 1263–1268.
Georgakis, G. V., Li, Y., Humphreys, R., Andreeff, M., O’Brien, S., Younes, M., Carbone, A., Albert, V., and Younes, A. (2005). Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib = induced cell death. Br J Haematol 130, 501–510.
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash DC) 293, 876–880.
Greten, F. R., Echmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F., and Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296.
Guo, F., Nimmanapalli, R., Paranawithana, S., Wittman, S., Griffin, D., Bali, P., O’Bryan, E., Fumero, C., Wang, H. G., and Bhalla, K. (2002). Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419–3426.
Hay, N. and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev 18, 1926–1945.
Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 4, 648–657.
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G., Masucci, M., Pramanik, A., and Selivanova, G. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10, 1321–1328.
Jiang, X., Kim, H.-E., Shu, H., Zhao, Y., Zhang, H., Kofron, J., Donnelly, J., Burns, D., Ng, S.-c., Rosenberg, S., and Wang, X. (2003). Distinctive roles of PHAP proteins and prothymosin-t in a death regulatory pathway. Science 299, 223–226.
Johnstone, R. W., Ruefli, A., and Lowe, S. W. (2002). Apoptosis: A link between cancer genetics and chemotherapy. Cell 108, 153–164.
Jones, H. E., Gee, J. M., Taylor, K. M., Barrow, D., Williams, H. D., Rubini, M., and NIcholson, R. I. (2005). Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer 12 (Suppl 1), S173–S182.
Jost, M., Huggett, T. M., Kari, C., Boise, L. H., and Rodeck, U. (2001). Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem 276, 6320–6326.
Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D. J., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O’Brien, S. G., Russell, N., and Fischer, T. (2002a). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346, 645–652.
Kantarjian, H. M., Talpaz, M., O’Brien, S., Smith, T. L., Giles, F. J., Faderl, S., Thomas, D. A., Garcia-Manero, G., Issa, J. P., Andreeff, M., Kornblau, S. M., Koller, C., and Beran, M. 2002b. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8, 2177–2187.
Karin, M. and Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nat Immunol 3, 221–227.
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., and Heise, C. (2000). A controlled trial of intratumoral ONYX-015, a selectively -replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6, 879–885.
Kim, R. (2005). Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103, 1551–1560.
Klionsky, D. J. and Emr, S. D. (2000). Autophagy as a regulated pathway of cellular degradation. Science 290, 1717–1721.
Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K., and Inaba, T. (2004). Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24, 6172–6183.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J., Bonzon, C., Sullivan, B., Green, D., and Newmeyer, D. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17, 525–535.
Le, L. (2004). Phase 1 study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin’s lymphoma. In American Society of Clinical Oncology Annual Meeting, New Orleans.
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., and Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192.
Leu, C. M., Chang, C., and Hu, C. (2000). Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 19, 1665–1675.
Ley, R., Balmanno, K., Hadfield, K., Weston, C., and Cook, S. J. (2003). Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278, 18811–18816.
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., and Harran, P. G. (2004). A small molecule Smac mimic potentiates TRAIL- and TNF-alpha-mediated cell death. Science 305, 1471–1474.
Li, P., Nijihawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489.
Liu, Y. Z., Boxer, L. M., and Latchman, D. S. (1999). Activation of the Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids Res 27, 2086–2090.
Locksley, R. M., Killeen, N., and Lenardo, M. J. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501.
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., and Auberger, P. (2003). Phosphorylation of Bim-EL by Erk 1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22, 6785–6793.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139.
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Seino-Noda, H., Sakata, M., Motoyama, T., Kurachi, H., Testa, J. R., Tasaka, K., and Murata, Y. (2004a). Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 10, 7645–7654.
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Sakata, M., Motoyama, T., Kurachi, H., Tasaka, K., and Murata, Y. (2004b). Inhibition of NF-, B increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279, 23477–23485.
Milella, M., Precupanu, C. M., Gregorj, C., Ricciardi, M. R., Petrucci, M. T., Kornblau, S. M., Tafuri, A., and Andreeff, M. (2005). Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic antileukemic effects. Curr Pharm Des 11, 2779–2795.
Morgensztern, D. and McLeod, H. (2005). PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Canc Drugs 16, 797–803.
Nakanishi, C. and Toi, M. (2005). Nuclear factor-NB inhibitors as sensitizers to anticancer drugs. Nat Rev 5, 297309.
Nelson, D., Tan, T.-T., Rabson, A. B., Anderson, D., Degenhardt, K., and White, E. (2004). Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18, 2095–2107.
Nguyen, J. T. and Wells, J. A. (2003). Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci USA 100, 7533–7538.
Nikolovska-Coleska, Z., Xu, L., Hu, Z., Tomita, Y., LI, P., Roller, P. P., Wang, R., Fang, X., Guo, R., and Zhang, M. (2004). Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47, 2430–2440.
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364, 806–809.
Okada, H. and Mak, T. W. (2004). Pathways of apoptotic and non-apoptotic death in tumor cells. Nature Rev Cancer 4, 592–603.
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., and Ng, S. E. A. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681.
Oost, T. K., Sun, C., Armstrong, R. C., Al-Assaad, A.-S., Betz, S. F., Deckwerth, T. L., Ding, H., Elmore, S. W., Meadows, R. P., Olejniczak, E. T., Oltersdorf, T., Rosenberg, S. H., Shoemaker, A. R., Tomaselli, K. J., Zou, H., and Fesik, S. W. (2004). Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47, 4417–4426.
Park, C.-M., Sun, C., Olejniczak, E. T., Wilson, A. E., Meadows, R. P., Betz, S. F., Elmore, S. W., and Fesik, S. W. (2005). Non-peptidic small molecule inhibitors of XIAP. Bioorg Med Chem Lett 15, 771–775.
Perez-Soler, R. (2004). The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10, 4238s–4240s.
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466.
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, I., vonKerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T., and Albert, V. (2005). HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92, 1430–1441.
Qiu, J., Levin, L. R., Buck, J., and Reidenberg, M. M. (2002). Different pathways of cell killing by gossypol enantiomers. Exp Biol Med 227, 398–401.
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112, 1809–1820.
Rajkumar, S. V., Richardson, P. G., Hideshima, T., and Anderson, K. C. (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23, 630–639.
Reed, J. C. and Pellecchia, M. (2005). Apoptosis-based therapies for hematologic malignancies. Blood 106, 408–418.
Rinehart, J., Adjei, A. A., and Lorusso, P. M. (2004). Multicenter phase 2 study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22, 4456–4462.
Rundall, B. K., Denlinger, C. E., and Jones, D. R. (2004). Combined histone deacetylase and NF-0B inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136, 416–425.
Salvesen, G. S. and Duckett, C. S. (2002). IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 3, 401–410.
Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M. J., I. M., P., Kitada, S., Scott, F. L., Bailly-Maitre, B., Glinsky, G., Scudiero, D., Sausville, E., Salvesen, G., Nefzi, A., Ostresh, J. M., Houghten, R. A., and Reed, J. C. (2004). Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35.
Scholz, C., Wieder, T., Starck, L., Essmann, F., Schultz-Osthoff, K., Dorken, B., and Daniel, P. T. (2005). Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24, 1904–1913.
Scott, S. L., Earle, J. D., and Gumerlock, P. H. (2003). Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res 63, 7190–7196.
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., and Sawyers, C. L. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (Wash DC) 305, 399–401.
Shangary, S. and Johnson, D. E. (2002). Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release and activation of cell death. Biochemistry 41, 9485–9495.
Shariat, S. F., Desai, S., Song, W., Khan, T., Zhao, J., Nguyen, C., Foster, B. A., Greenberg, N., Spencer, D. M., and Slawin, K. M. (2001). Adenovirus-mediated transfer of inducible caspases: a novel ‘death switch’ gene therapeutic approach of prostate cancer. Cancer Res 61, 2562–2571.
Shi, Y. (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9, 459–470.
Shiozaki, E. N., Chai, J., Rigotti, D. J., Riedl, S. J., Li, P., Srinivasula, S. M., Alnemri, E. S., Frirman, R., and Shi, Y. (2003). Mol Cell 11, 519–527.
Sordella, R., Bell, D. W., Haber, D. A., and Settleman, J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167.
Stoklosa, T., Slupianek, A., Datta, M., Nieborowska-Skorska, M., Nowicki, M. O., Koptyra, M., and Skorski, T. (2004). BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 3, 1463–1472.
Sun, H., Nikolovska-Coleska, Z., Chen, J., Yang, C. Y., Tomita, Y., Pan, H., Yoshioka, Y., Krajewski, K., Roller, P. P., and Wang, S. (2005). Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg Med Chem Lett 15, 793–797.
Suzuki, M., Youle, R. J., and Tjandra, N. (2000). Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645–654.
Tan, T.-T., Degenhardt, K., Nelson, D. A., Beaudoin, B., Nieves-Neira, W., Bouillet, P., Villunger, A., Adams, J. M., and White, E. (2005). Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7, 227–238.
Thallinger, C., Wolschek, M. F., Maierhofer, H., Skvara, H., Pehamberger, H., and Monia, B. P. (2004). Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 10, 4185–4191.
Thomas, S. M. and Grandis, J. R. (2004). Pharmacokinetics and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30, 255–268.
Thompson, N. and Lyons, J. (2005). Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5, 350–356.
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., and Klein, C. (2004). In vivo activation of the p53-pathway by small-molecule antagonists of MDM2. Science (Wash DC) 303, 844–848.
Vignot, S., Faivre, S., Aguirre, D., and Raymond, E. (2005). mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16, 525–537.
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., and Korsmeyer, S. J. (2004). Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470.
Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., and Boldin, M. P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17, 331–367.
Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., and Marais, R. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867.
Wang, Z., Cuddy, M., and Samuel, T., et al. (2004). Cellular, biochemical, and genetic analysis of mechanism of small-molecule IAP inhibitors. J Biol Chem 279, 48168–48176.
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowlev, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesenskv, A., Riedl, B., Post, L. E., Bollag, G., and Trail, P. A. (2004). BAY43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099–7109.
Willis, S. N. and Adams, J. M. (2005). Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17, 1–9.
Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., and Huang, D. C. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19, 1294–1305.
Wong, S. F. (2005). Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 6, 684–694.
Wu, G., Chai, J., Suber, T. L., Wu, J. W., Du, C., Wang, X., and Shi, Y. (2000). Structural basis of IAP recognition by Smac/DIABLO. Nature 408, 1008–1012.
Wu, T., Wagner, K. W., Bursulaya, B., Schultz, P. G., and Deveraux, Q. L. (2003). Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 10, 759–767.
Wyllie, A. H. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 284, 555–556.
Xu, Y. M., Wang, L. F., Jia, L. T., Qiu, X. C., Zhao, J., Yu, C. J., Zhang, R., Zhu, F., Wang, C. J., and Jin, B. Q. (2004). A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 173, 61–67.
Yamauchi, T., Ueki, K., Tobe, K., Tamemoto, H., Sekine, N., Wada, M., Honjo, M., Takahashi, M., Takahashi, T., Hirai, H., Tsushima, T., Akanuma, Y., Fujita, T., Komuro, I., Yazaki, Y., and Kadowaki, T. (1998). Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Endocr J 45 (Suppl), S27–S31.
Yang, L., Mashima, T., Sato, S., M., M., Sakamoto, H., Yamori, T., Oh-Hara, T., and Tsuruo, T. (2003). Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63, 831–837.
Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003). Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 100, 15077–15082.
Zaffaroni, N., Pennati, M., and Daidone, M. G. (2005). Survivin as a target for new anticancer interventions. J Cell Mol Med 9, 360–372.
Zapata, J. M., Pawlowski, K., Haas, E., Ware, C. F., Godzik, A., and Reed, J. C. (2001). A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 276, 24242–24252.
Zong, W.-X., Lindsten, T., Ross, A. J., MacGregor, G. R., and Thompson, C. B. (2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15, 1481–1486.
Zong, W.-X., Ditsworth, D., Bauer, D. E., Wang, Z.-Q., and Thompson, C. B. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18, 1272–1282.
Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405–413.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Tan, TT., White, E. (2008). Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells. In: Programmed Cell Death in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, vol 615. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6554-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6554-5_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6553-8
Online ISBN: 978-1-4020-6554-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)